CellCarta is the first global CRO to offer the Olink® Proximity Extension Assay (PEA) technology for clinical trials.
The unmatched high-multiplex technique allows for the quantification of protein biomarkers:
The integration of the Olink® Signature Q100 instruments with the Target 96 & Target 48 panels into laboratories will allow us to support biological mechanism studies driven by low abundant biomarkers such as immuno-oncology. Our team will address proteomic biomarkers needs for clinical trials, helping you investigate the mechanism of action of your new therapeutic or narrow down your list of potential clinical biomarkers.
The Proximity Extension Assay (PEA)’s dual recognition approach is based on matched pairs of antibodies labeled with complementary DNA oligonucleotide tags. Once the target is bound, the oligonucleotides brought into proximity hybridize and are extended by standard PCR. This piece of DNA “barcode” created is unique for each antibody pair and is then amplified by quantitative PCR (qPCR).
The Olink® Target 96 & Target 48 panels focus around specific disease areas or biological processes, and each enable the relative quantification of up to 92 carefully selected proteins across up to 88 samples simultaneously, using only 1µL of sample.